Dr Shao-An Xue has been in the field of viral oncology and cancer immunotherapy for 20 years, and has successfully developed a new strategy for cancer immunotherapy based on T cell receptor (TCR) gene transfer. He has been able to demonstrate that T cells transduced with a TCR specific for the Wilm’s tumor antigen (WT1-TCR) can recognize their specific targets and selectively kill leukemia progenitor cells, without damage to normal CD34+ cells. In vivo studies have shown that these TCR-engineered patient’s T cells can eliminate leukemia progenitor cells in situations where control T cells prove ineffective. He received George Brecher New Investigator Award from the International Society for Experimental Hematology (ISEH) in 2005.Apart from developing the leukemia specific WT1-TCR, Dr Xue has also developed many other tumor specific TCRs, including EBV-TCR, CMV-TCR and HBV-TCR, and all of these TCRs are in the first in man clinical trials now. Due to his contribution and influence in the field of TCR immunogene therapy of cancer, he has been invited as editorial board member on several international journals, including Journal of Immunotherapy applications, Science Journal of Clinical Medicine, Annals of Vaccines and Immunization, World Journal of Hematology and Journal of Hematological Malignancies. Dr Xue received his PhD degree in Viral Oncology from Imperial College London, United Kingdom, in 1999.
1) Cancer Immunotherapy
2) Cellular immunology
3) Molecular biology
1. Tan PH, Tyrrell HE, Gao L, Xu D, Quan J, Gill D, Rai L, Ding Y, Plant G, Chen Y, Xue JZ, Handa AI, Greenall MJ, Walsh K, Xue SA*. Adiponectin receptor signaling on dendritic cells blunts antitumor immunity. Cancer Res. 2014. 74(20): 5711-5722. (*Corresponding author) (Impact Factor: IF: 9.28).
2. Xue SA*, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ. Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology. 2013. 2(1): e22590. (*Corresponding author, IF: 6.28).
3. Xue SA*, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E & Stauss HJ. Development of a WT1-TCR for clinical trials: Engineered patient T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 2010. 95(1): 126-134. (*Corresponding author) (IF: 6.4).
4. Xue SA & Griffin BE. Update on the Epstein-Barr virus-associated malignancy, endemic Burkitt’s lymphoma. In: Molecular Biology of Tumour Virus Gene Products. Edited by Kenichi Yoshida. Research Signpost. Kerala, India. ISBN: 978-81-308-0324-1. 2010. pp1-28. (www.ressign.com/UserBookDetail.aspx?bkid=846&catid=196).
5. Xue SA, Bendle GM, Holler A and Stauss HJ. Generation and characterisation of transgenic mice expressing a T cell receptor specific for the tumour-associated antigen MDM2. Immunology. 2008. 124(3): 315-321. (IF: 3).
6. Xue SA & Griffin BE. Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication. Nucleic Acids Res. 2007. 35(10): 3391-3406. (IF: 8.8).
7. Bendle GM*, Xue SA*, Holler A and Stauss HJ. A Study of T Cell Tolerance to the Tumor-Associated Antigen MDM2: Cytokines Can Restore Antigen Responsiveness, but not High Avidity T Cell Function. PLoS One. 2007. 2(4): e353. (*Joint first author, IF: 4).
8. Tan PH*, Xue SA*, Wei B, Holler A, Voss R-H & George AJT. Changing viral tropism using immunoliposomes alters the stability of gene expression: implication for viral vector design. Molecular Medicne. 2007. 13(3-4): 216-226. (*Joint first author, IF: 5).
9. Xue SA* & Stauss HJ. Enhancing immune responses for cancer therapy. Cell. Mol. Immunol. 2007. 4(3): 173-184. (*Corresponding author). (IF: 4).
10. Xue SA, Gao L, Hart D, Gilmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss HJ. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005. 106(9): 3062-3067. (IF: 10). 6
11. Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ. Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol. 2005. 139(2):167-172. (IF: 3).
12. Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Stauss HJ, Morris E. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis. 2004. 33(3):288-290. (IF: 3).
13. Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Morris E, Stauss HJ. Use of the allogeneic TCR repertoire to enhance anti-tumor immunity. J Biol Regul Homeost Agents. 2004. 18(2):131-133. (IF: 3).
14. Xue SA, Jones MD, Lu QL, Middeldorp JM & Griffin BE. Genetic Diversity: Frameshift Mechanisms Alter Coding of a Gene (Epstein-Barr Virus LF3 Gene) That Contains Multiple 102-Base-Pair Direct Sequence Repeats. Mol. Cell. Biol. 2003. 23(6): 2192-2201. (IF: 6).
15. Xue SA, Lampert IA, SHaldane JS, Bridger JE. & Griffin BE. Epstein-Barr Virus Gene Expression in Human Breast Cancer: Protagonist or Passenger? Br. J. Cancer. 2003. 89(1): 113-119. (IF: 5).